An observational study in Leukemia, Myeloid, Neoplasm Metastasis and Leukemia, Lymphoid, sponsored by National Cancer Institute (NCI). Completed at 17 sites in 2 countries. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by National Cancer Institute (NCI) · Observational
Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes.
The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.
Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile, and/or saliva) will be collected from cancer patients enrolled on approved clinical trials, in accordance with the local protocol. These trials are being conducted at outside institutions, in collaboration with the National Cancer Institute (NCI) and the samples will be sent to the NCI for pharmacological analysis, involving determination of parent drug and/or metabolite concentrations and subsequent pharmacokinetics and statistical data analysis. This study aims to further characterize the clinical pharmacokinetic behavior of select cancer therapeutics. Future collaborators will be added via the protocol amendment procedure.
2,432 studies on the registry are indexed under Leukemia, Myeloid; 205 are open to participants now.
This study's enrollment of 2,579 is above the median of 117 across 290 observational studies indexed under Leukemia, Myeloid.
Browse Leukemia, Myeloid studies →National Cancer Institute (NCI) is the lead sponsor of 3,554 studies on the registry; 334 are open to participants now.
Of its 407 completed or terminated interventional studies of FDA-regulated products, 370 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer@@@
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer at institutions outside of the intramural NCI are eligible for inclusion, provided that they have consented to pharmacological analysis in the original consent form.
EXCLUSION CRITERIA:
None anticipated at this time.
Patients on approved clinical trials
Drug and/or metabolite concentration
To quantitate drug and/or metabolite concentrations in human blood samples
Time frame: Ongoing
Pharmacological behavior of agents
To characterize the clinical pharmacological behavior of agents
Time frame: Ongoing
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →